Exemestane-TEVA coated tablets 25 mg. №30


Manufacturer: Ireland

Adjuvant therapy in women with invasive early-stage breast cancer with a positive test for estrogen receptors in the postmenopausal period after 2-3 yEars and Nose of initial adjuvant therapy with tamoxifen.
Treatment of advanced breast cancer in women with natural or induced postmenopausal status who have been diagnosed with disease progression after antiestrogen therapy. No efficacy was demonstrated in patients with a negative test for estrogen receptors.



Exemestane-TEVA Composition:
active substance: exemestane, 1 film-coated tablet containing 25 mg of exemestane, excipients: mannitol (E 421), copovidone, crospovidone, microcrystalline cellulose, colloidal anhydrous silica, sodium starch glycolate (type A), magnesium; shell Advantia Prime White 190100BA01: hypromellose, macrogol 400, titanium dioxide (E 171).
Dosage form:

Exemestane-TEVA Main physical and chemical properties:
round biconvex tablets of white or almost white color, film-coated, embossed with 25 on one side and smooth on the other.

Exemestane-TEVA Manufacturer:
Air Pharma Co., Ltd. for Teva Pharmaceuticals SR, Ireland / Czech Republic.

Pharmacotherapeutic group:
Hormone antagonists and similar drugs. Enzyme inhibitors.

Pharmacological properties:
Pharmacodynamics. Exemestane is an irreversible steroid aromatase inhibitor, similar in structure to the natural substance androstenedione. In postmenopausal women, estrogens are produced primarily by the conversion of androgens to estrogens by the enzyme aromatase in peripheral tissues. Blocking the production of estrogen by inhibiting aromatase is an effective and selective method of treating hormone-dependent breast cancer in postmenopausal women. In postmenopausal women, exemestane significantly reduces the concentration of estrogen in the serum, starting with a dose of 5 mg; the maximum reduction (> 90%) is reached at a dose of 10-25 mg. In postmenopausal patients diagnosed with breast cancer who received 25 mg daily, the overall level of aromatase was reduced by 98%. Exemestane has no progestogenic or estrogenic activity. Low androgenic activity, probably related to the 17-hydroderivative, was observed mainly with the use of the drug in high doses. With long-term daily use, exemestane did not affect the biosynthesis of hormones such as cortisol or aldosterone. In this regard, there is no need for replacement therapy with glucocorticoids and mineralocorticoids. A slight increase in the levels of LH and FSH in the serum is observed even at low doses; this effect, however, is expected for drugs of this pharmacological group; It probably develops on the principle of feedback, at the level of the pituitary gland: a decrease in estrogen concentration stimulates the secretion of gonadotropins by the pituitary gland (also in postmenopausal women). Adjuvant therapy of early stages of breast cancer . The tendency to improve overall life expectancy is better for exemestane compared to tamoxifen.